PUBLIC COMPANY
save$CGEMCullinan Therapeutics, Inc.
$CGEM21.38-5.06%Cambridge, MA, USupdated 4h ago
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
2Phase 1
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
- phase1A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
- phase1CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- phase1A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
- phase1A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma
- phase1A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis
- phase2A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
- phase1CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Insider activity
source: SEC Form 4open-market buys + sells
- Mar 5, 26SELLMichaelson Jennifer· Chief Scientific Officer−$125K↗
- Feb 25, 26SELLMichaelson Jennifer· Chief Scientific Officer−$25K↗
- Feb 24, 26SELLAHMED NADIM· President and CEO−$196K↗
- Feb 24, 26SELLJones Jeffrey Alan· Chief Medical Officer−$66K↗
- Feb 24, 26SELLSUMER JACQUELYN L· Chief Legal Officer−$52K↗
- Feb 24, 26SELLMichaelson Jennifer· Chief Scientific Officer−$52K↗
- Feb 23, 26SELLMichaelson Jennifer· Chief Scientific Officer−$25K↗
routine RSU / option mechanics (2)
- Mar 5, 26option exerciseMichaelson Jennifer · Chief Scientific Officer4,000 sh
- Mar 5, 26option exerciseMichaelson Jennifer · Chief Scientific Officer4,000 sh
🐶 Hiring Signal
next earnings Nov 5, 2026
News
- Vertex’s latest autoimmune TCE play involves $28M upfront to AbCelleraAbCellera’s T-cell engager platform has reeled in a second client this summer, with Vertex paying $28 million upfront for a collaboration that will include autoimmune conditions.fiercebiotech · 22d ago
Data sources
last refreshed 3m ago
Found something off?
comments(0)
5-min edit window · permanent after that